Aura Biopharm
Norway - OsloBiotechnology
Focus: Aura Biopharm is a Norwegian biotech company developing a monoclonal antibody therapeutic targeting thrombosis and fetal loss in anti-phospholipid syndrome, a cardiovascular indication with significant unmet medical need.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Open Jobs
7+7 this month
Growing — net +7 jobs in 30d
7 jobs added vs 0 removed. Steady team buildout.
Should You Work at Aura Biopharm?
AI assessmentAura Biopharm represents a speculative early-stage opportunity suitable only for risk-tolerant candidates who value scientific innovation and equity upside over near-term stability or hiring momentum.
Why Work Here
- Opportunity to work on a novel, mechanism-based antibody in a high-unmet-need cardiovascular indication with limited treatment options
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aura Biopharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.